[go: up one dir, main page]

CY2015009I2 - Ινδολινονες υποκατεστημενες στη θεση 6, η παραγωγη αυτων και η χρηση αυτων ως φαρμακευτικα μεσα - Google Patents

Ινδολινονες υποκατεστημενες στη θεση 6, η παραγωγη αυτων και η χρηση αυτων ως φαρμακευτικα μεσα

Info

Publication number
CY2015009I2
CY2015009I2 CY2015009C CY2015009C CY2015009I2 CY 2015009 I2 CY2015009 I2 CY 2015009I2 CY 2015009 C CY2015009 C CY 2015009C CY 2015009 C CY2015009 C CY 2015009C CY 2015009 I2 CY2015009 I2 CY 2015009I2
Authority
CY
Cyprus
Prior art keywords
pharmaceuticals
production
indolinones
substituted
indolinones substituted
Prior art date
Application number
CY2015009C
Other languages
English (en)
Other versions
CY2015009I1 (el
Original Assignee
Δικαιούχου:
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35079161&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2015009(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Δικαιούχου: filed Critical Δικαιούχου:
Publication of CY2015009I2 publication Critical patent/CY2015009I2/el
Publication of CY2015009I1 publication Critical patent/CY2015009I1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
CY2015009C 2004-05-20 2023-09-28 Ινδολινονες υποκατεστημενες στη θεση 6, η παραγωγη αυτων και η χρηση αυτων ως φαρμακευτικα μεσα CY2015009I1 (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2004150979 2004-05-20

Publications (2)

Publication Number Publication Date
CY2015009I2 true CY2015009I2 (el) 2024-09-20
CY2015009I1 CY2015009I1 (el) 2024-09-20

Family

ID=35079161

Family Applications (4)

Application Number Title Priority Date Filing Date
CY20121100621T CY1113010T1 (el) 2004-05-20 2012-07-11 Ευσταθης κρυσταλλος ενωσης 4-οξοκινολινης
CY2015009C CY2015009I1 (el) 2004-05-20 2023-09-28 Ινδολινονες υποκατεστημενες στη θεση 6, η παραγωγη αυτων και η χρηση αυτων ως φαρμακευτικα μεσα
CY20231100714T CY1126560T1 (el) 2004-05-20 2023-12-05 Συνδυασμος ο οποιος περιλαμβανει εναν ευσταθη κρυσταλλο μιας ενωσης 4-οξοκινολινης
CY2024008C CY2024008I1 (el) 2004-05-20 2024-03-19 Συνδυασμος ο οποιος περιλαμβανει εναν ευσταθη κρυσταλλο μιας ενωσης 4-οξοκινολινης

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20121100621T CY1113010T1 (el) 2004-05-20 2012-07-11 Ευσταθης κρυσταλλος ενωσης 4-οξοκινολινης

Family Applications After (2)

Application Number Title Priority Date Filing Date
CY20231100714T CY1126560T1 (el) 2004-05-20 2023-12-05 Συνδυασμος ο οποιος περιλαμβανει εναν ευσταθη κρυσταλλο μιας ενωσης 4-οξοκινολινης
CY2024008C CY2024008I1 (el) 2004-05-20 2024-03-19 Συνδυασμος ο οποιος περιλαμβανει εναν ευσταθη κρυσταλλο μιας ενωσης 4-οξοκινολινης

Country Status (33)

Country Link
US (7) US7635704B2 (el)
EP (4) EP3281939B1 (el)
JP (1) JP3754064B2 (el)
KR (1) KR20080064909A (el)
CN (1) CN1956961B (el)
AR (2) AR049280A1 (el)
AU (1) AU2005245296B2 (el)
BE (1) BE2024C511I2 (el)
BR (1) BRPI0510114B8 (el)
CA (1) CA2566922C (el)
CY (4) CY1113010T1 (el)
DK (2) DK3281939T3 (el)
ES (2) ES2388441T3 (el)
FI (2) FI3281939T3 (el)
FR (1) FR23C1040I1 (el)
HR (2) HRP20120681T1 (el)
HU (2) HUE064615T2 (el)
IL (1) IL179250A0 (el)
LT (2) LT3281939T (el)
LU (1) LUC00334I2 (el)
MX (1) MXPA06013405A (el)
MY (1) MY134672A (el)
NO (8) NO339223B1 (el)
NZ (1) NZ551839A (el)
PE (2) PE20060358A1 (el)
PL (2) PL3281939T3 (el)
PT (2) PT1636190E (el)
RS (2) RS64845B1 (el)
RU (1) RU2330845C1 (el)
SI (2) SI3281939T1 (el)
TW (1) TWI329015B (el)
WO (1) WO2005113508A1 (el)
ZA (1) ZA200610647B (el)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6891227B2 (en) 2002-03-20 2005-05-10 International Business Machines Corporation Self-aligned nanotube field effect transistor and method of fabricating same
BRPI0306214B1 (pt) * 2002-11-20 2017-08-08 Japan Tobacco Inc. 4-oxoquinoline compound and use of this as a hiv integrase inhibitor
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
WO2007063869A1 (ja) * 2005-11-30 2007-06-07 Japan Tobacco Inc. 高純度キノロン化合物の製造方法
AU2013203476C1 (en) * 2005-12-30 2016-11-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
US20090233964A1 (en) * 2005-12-30 2009-09-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
KR101524165B1 (ko) * 2005-12-30 2015-06-01 길리애드 사이언시즈, 인코포레이티드 Ｈｉｖ 인테그라제 억제제의 약동학을 개선하기 위한 방법
US20090018162A1 (en) * 2006-02-01 2009-01-15 Yuji Matsuzaki Use of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or salt thereof for treating retrovirus infection
WO2007092802A1 (en) * 2006-02-09 2007-08-16 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and gs 9137
ES2531190T3 (es) 2006-03-06 2015-03-11 Japan Tobacco Inc Método para producir un compuesto de 4-oxoquinolina
WO2007102499A1 (ja) 2006-03-06 2007-09-13 Japan Tobacco Inc. ４－オキソキノリン化合物の製造方法
SI2049506T2 (sl) 2006-07-07 2024-07-31 Gilead Sciences, Inc. Modulatorji farmakokinetičnih lastnosti terapevtikov
HRP20090213B1 (hr) 2006-09-12 2016-12-02 Gilead Sciences, Inc. Postupak i međuprodukti u pripravi inhibitora integraze
ES2779826T3 (es) * 2007-02-23 2020-08-20 Gilead Sciences Inc Moduladores de propiedades farmacocinéticas de agentes terapéuticos
CN101686972B (zh) * 2007-06-29 2013-08-14 吉里德科学公司 治疗用组合物和方法
CN103356622A (zh) * 2007-06-29 2013-10-23 吉里德科学公司 治疗用组合物及其用途
AR068403A1 (es) * 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa
MX342377B (es) 2008-05-02 2016-09-27 Gilead Sciences Inc Uso de particulas trasportadoras solidas para mejorar la capacidad de procesamiento de un agente farmaceutico.
KR101645759B1 (ko) 2009-02-06 2016-08-04 길리애드 사이언시즈, 인코포레이티드 조합 요법용 정제
WO2010137032A2 (en) * 2009-05-14 2010-12-02 Matrix Laboratories Ltd. Novel polymorphic forms of elvitegravir and its pharmaceutically acceptable salts
WO2011004389A2 (en) * 2009-06-18 2011-01-13 Matrix Laboratories Ltd An improved process for the preparation of elvitegravir
CN102212032B (zh) * 2011-04-20 2013-07-31 复旦大学 一种5-羟基喹诺酮类衍生物及其制备方法和用途
BR112015000187A2 (pt) 2012-07-06 2017-06-27 Genentech Inc benzamidas substituídas com n e métodos de uso das mesmas
AU2013296289B2 (en) 2012-08-03 2017-10-05 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
CN103819402B (zh) * 2012-11-17 2016-03-30 上海迪赛诺化学制药有限公司 埃替拉韦中间体及其制备方法和应用
CN103864682B (zh) * 2012-12-18 2016-12-28 上海迪赛诺化学制药有限公司 一种制备iii型埃替拉韦晶体的方法
SI3067358T1 (sl) 2012-12-21 2019-12-31 Gilead Sciences, Inc. Policiklične spojine karbamoilpiridona in njihova farmacevtska uporaba
AU2014286993B2 (en) 2013-07-12 2018-10-25 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their use for the treatment of HIV infections
NO2865735T3 (el) 2013-07-12 2018-07-21
CN105315203A (zh) * 2014-06-06 2016-02-10 上海迪赛诺化学制药有限公司 一种v型埃替拉韦晶体及其制备方法
NO2717902T3 (el) 2014-06-20 2018-06-23
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
CA2980362C (en) 2015-04-02 2020-02-25 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
CN106008195B (zh) * 2016-05-19 2018-08-03 绍兴文理学院 一种2，4-二氟-5-碘苯甲酸的制备方法
EP3984536B1 (en) * 2020-10-19 2025-06-25 Centre national de la recherche scientifique Inhibition of the hiv-1 replication by compounds directed against a new target of the viral cycle

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3472859A (en) * 1966-11-01 1969-10-14 Sterling Drug Inc 1-alkyl-1,4-dihydro-4-oxo-3 quinoline-carboxylic acids and esters
JPS567162B1 (el) 1970-09-14 1981-02-16
JPS4826772A (el) 1971-08-11 1973-04-09
JPS6450979A (en) 1987-08-21 1989-02-27 Hitachi Shipbuilding Eng Co Method for discriminating whistle sound
JPH0651229B2 (ja) 1989-07-31 1994-07-06 新日本製鐵株式会社 プラズマアーク溶接方法および装置
IL100555A (en) * 1991-02-07 2000-08-31 Hoechst Marion Roussel Inc N-substituted quinoline derivatives their preparation their use for the preparation of medicaments and the pharmaceutical compositions containing them
JP2993316B2 (ja) 1992-05-27 1999-12-20 宇部興産株式会社 アリール基又は複素芳香環基置換アミノキノロン誘導体及びエイズ治療剤
NO304832B1 (no) * 1992-05-27 1999-02-22 Ube Industries Aminokinolonderivater samt middel mot HIV
JPH06199835A (ja) 1993-01-08 1994-07-19 Hokuriku Seiyaku Co Ltd ８−ジフルオロメトキシキノリン−３−カルボン酸誘導体
JPH06271568A (ja) 1993-03-22 1994-09-27 Hokuriku Seiyaku Co Ltd ７−フェニルピペラジニルキノリン−３−カルボン酸誘導体
NZ287550A (en) * 1994-07-18 1998-01-26 Ube Industries 8-trifluoromethylquinolinecarboxylic acid derivatives; medicaments
JP2930539B2 (ja) 1994-07-18 1999-08-03 三共株式会社 トリフルオロメチルキノリンカルボン酸誘導体
JPH0826772A (ja) 1994-07-22 1996-01-30 Sony Corp 融着用ガラス、その製造方法及び製造装置、並びに磁気ヘッドの製造方法
ES2171260T3 (es) 1996-04-12 2002-09-01 Us Gov Health & Human Serv Compuestos derivados de acridona utiles como agentes antineoplasicos y antirretroviricos.
FR2761687B1 (fr) * 1997-04-08 2000-09-15 Centre Nat Rech Scient Derives de quinoleines, possedant notamment des proprietes antivirales, leurs preparations et leurs applications biologiques
JP3776203B2 (ja) 1997-05-13 2006-05-17 第一製薬株式会社 Ｉｃａｍ−１産生阻害剤
GB9721964D0 (en) * 1997-10-16 1997-12-17 Pfizer Ltd Isoquinolines
US6399629B1 (en) 1998-06-01 2002-06-04 Microcide Pharmaceuticals, Inc. Efflux pump inhibitors
SE9802549D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
US6248739B1 (en) * 1999-01-08 2001-06-19 Pharmacia & Upjohn Company Quinolinecarboxamides as antiviral agents
US6248736B1 (en) * 1999-01-08 2001-06-19 Pharmacia & Upjohn Company 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents
PE20011349A1 (es) 2000-06-16 2002-01-19 Upjohn Co 1-aril-4-oxo-1,4-dihidro-3-quinolincarboxamidas como agentes antivirales
US6559145B2 (en) * 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
EP1333831A2 (en) 2000-10-12 2003-08-13 Merck & Co., Inc. Aza-and polyaza-naphthalenyl ketones useful as hiv integrase inhibitors
JP2004517860A (ja) 2000-10-12 2004-06-17 メルク　エンド　カムパニー　インコーポレーテッド Ｈｉｖインテグラーゼ阻害薬として有用なアザ−およびポリアザ−ナフタレニルカルボキサミド類
PL365027A1 (en) * 2001-03-01 2004-12-27 Shionogi & Co, Ltd. Nitrogen-containing heteroaryl compounds having hiv integrase inhibitory activity
JP2002293745A (ja) 2001-03-29 2002-10-09 St Marianna Univ School Of Medicine 慢性関節リウマチ治療剤
US20030138483A1 (en) * 2001-05-25 2003-07-24 Sergio Petriconi Soft elastic capsules and compositions thereof
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
FR2827600A1 (fr) 2001-07-20 2003-01-24 Lipha Derives acides de quinolone et leurs applications en therapeutique
RU2206564C1 (ru) * 2002-03-07 2003-06-20 Общество с ограниченной ответственностью "Поливит" Способ получения этилового эфира 6-фтор-7-хлор-1,4-дигидро-4-оксо-3-хинолинкарбоновой кислоты
JP4035765B2 (ja) 2002-10-31 2008-01-23 横河電機株式会社 フーリエ変換型赤外線分光計
JP3567162B1 (ja) 2002-11-20 2004-09-22 日本たばこ産業株式会社 ４−オキソキノリン化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用
BRPI0306214B1 (pt) * 2002-11-20 2017-08-08 Japan Tobacco Inc. 4-oxoquinoline compound and use of this as a hiv integrase inhibitor
WO2005113509A1 (en) * 2004-05-20 2005-12-01 Japan Tobacco Inc. Novel 4-oxoquinoline compound and use thereof as hiv integrase inhibitor
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
EP3287130A1 (en) * 2004-05-21 2018-02-28 Japan Tobacco Inc. Combinations comprising a 4-isoquinolone derivative and protease inhibitors

Also Published As

Publication number Publication date
EP3281939A1 (en) 2018-02-14
BRPI0510114A (pt) 2007-09-25
CA2566922C (en) 2011-01-11
FR23C1040I1 (fr) 2023-12-29
HUS2400006I1 (hu) 2024-04-28
KR20080064909A (ko) 2008-07-09
AR096100A2 (es) 2015-12-09
US20190185433A1 (en) 2019-06-20
US20220235009A1 (en) 2022-07-28
CN1956961B (zh) 2010-05-26
ZA200610647B (en) 2008-06-25
CA2566922A1 (en) 2005-12-01
FIC20240008I1 (fi) 2024-03-20
US20150361044A1 (en) 2015-12-17
US20180029989A1 (en) 2018-02-01
SI1636190T1 (sl) 2012-09-28
US20250091995A1 (en) 2025-03-20
DK1636190T3 (da) 2012-09-24
HUE064615T2 (hu) 2024-04-28
SI3281939T1 (sl) 2024-02-29
LUC00334I2 (el) 2024-07-01
NO20230913A1 (no) 2007-02-07
EP3281939B1 (en) 2023-10-18
JP3754064B2 (ja) 2006-03-08
NZ551839A (en) 2009-11-27
NO339223B1 (no) 2016-11-21
PT1636190E (pt) 2012-08-20
US20100204271A1 (en) 2010-08-12
NO347902B1 (no) 2024-05-06
ES2960824T3 (es) 2024-03-06
CY2024008I2 (el) 2024-09-20
HRP20231588T3 (hr) 2024-03-15
EP4299563A2 (en) 2024-01-03
LTC3281939I2 (el) 2025-04-25
NO20200873A1 (no) 2007-02-07
EP4299563A3 (en) 2024-02-28
US8981103B2 (en) 2015-03-17
PT3281939T (pt) 2023-11-22
PL3281939T3 (pl) 2024-03-18
RS64845B1 (sr) 2023-12-29
RU2330845C1 (ru) 2008-08-10
RS52375B (sr) 2012-12-31
CY2024008I1 (el) 2024-09-20
ES2388441T3 (es) 2012-10-15
NO20220690A1 (no) 2007-02-07
FI3281939T3 (fi) 2023-10-23
CY1126560T1 (el) 2024-09-20
EP1636190B1 (en) 2012-06-27
CN1956961A (zh) 2007-05-02
JP2006001927A (ja) 2006-01-05
MY134672A (en) 2007-12-31
NO20065790L (no) 2007-02-07
PL1636190T3 (pl) 2012-10-31
HK1083341A1 (en) 2006-06-30
IL179250A0 (en) 2007-03-08
BRPI0510114B8 (pt) 2021-05-25
NO20190051A1 (no) 2007-02-07
CY1113010T1 (el) 2016-04-13
US20060030710A1 (en) 2006-02-09
AR049280A1 (es) 2006-07-12
HRP20120681T1 (hr) 2012-09-30
EP2514746A1 (en) 2012-10-24
PE20060358A1 (es) 2006-05-12
AU2005245296A1 (en) 2005-12-01
WO2005113508A1 (en) 2005-12-01
AU2005245296B2 (en) 2010-08-12
PE20120361A1 (es) 2012-05-03
LTPA2024001I1 (el) 2024-04-10
TWI329015B (en) 2010-08-21
TW200600097A (en) 2006-01-01
NO20240384A1 (no) 2007-02-07
US7635704B2 (en) 2009-12-22
BE2024C511I2 (el) 2024-10-08
LT3281939T (lt) 2023-11-27
CY2015009I1 (el) 2024-09-20
BRPI0510114B1 (pt) 2020-09-15
EP1636190A1 (en) 2006-03-22
NO2024034I1 (no) 2024-07-15
NO20161297A1 (no) 2007-02-07
MXPA06013405A (es) 2007-03-01
DK3281939T3 (da) 2024-01-22

Similar Documents

Publication Publication Date Title
CY2015009I1 (el) Ινδολινονες υποκατεστημενες στη θεση 6, η παραγωγη αυτων και η χρηση αυτων ως φαρμακευτικα μεσα
CY2015009PI2 (el) Ινδολινονες υποκατεστημενες στη θεση 6, η παραγωγη αυτων και η χρηση αυτων ως φαρμακευτικα μεσα
CY2017006I1 (el) Αερολυμενες φθοροκινολονες και χρησεις αυτων
CY2019042I1 (el) Οφθαλμολογικες συνθεσεις και η χρηση τους
EP1933936A4 (en) IMPREGNATED ENVELOPE OF MEDICAMENT
DE602005004144D1 (de) Octahydropyrroloä3,4-cüpyrrolderivate und deren verwendung als antivirale mitteln
DOP2006000278A (es) Glicosilación en la región variable
DK2064334T3 (da) Aldehydtags, anvendelser deraf i site-specifik proteinmodificering
DE602004021904D1 (de) Gyraseinhibitoren und deren verwendungen
IS7881A (is) CHK-, PDK- og AKT-hindrandi pýrimidín, framleiðsla þeirra og notkun sem lyfjaefni
EP1824971A4 (en) GENETICALLY MODIFIED CLOSTRIDIAL GENES, PROTEINS ENCODED BY SUCH MODIFIED GENES AND USES THEREOF
ATE420072T1 (de) Neue alkyl-haltige 5-acylindolinone, deren herstellung und deren verwendung als arzneimittel
DE602005011593D1 (de) Substituierte diazaspiroä5.5üundecanderivate und deren verwendung als neurokininantagonisten
ATE548349T1 (de) In stellung 3 disubstituierte indol-2-on- pyridinderivate, ihre herstellung sowie ihre therapeutische anwendung
NL1031626A1 (nl) Verbindingen die bruikbaar zijn in therapie.
EP1951900A4 (en) SELF-ASSOCIATED SINGLE MOLECULE ARRAYS AND USES THEREOF
DE602004030564D1 (de) 2-substituierte phenyl-5,7-dialkyl-3,7-dihydropyrrolä2,3-dü pyrimidin-4-onderivate, deren herstellung und pharmazeutische verwendung
ATE531715T1 (de) 1,3-dihydro-2h-pyrroloä3.2-büpyridin-2-onderiva e,deren herstellung und deren therapeutische verwendungen
EP1870401A4 (en) 1,4-SUBSTITUTED PIPERAZINE DERIVATIVE
IS7980A (is) Díarýlmetýlídenpíperidínafleiður, framleiðsla þeirra og notkun
ATE542806T1 (de) Diarylmethylpiperazinderivate, deren herstellung und deren verwendung
DE602005020457D1 (de) Master-slave-flip-flop, trigger-flip-flop und zähler
FI20041641L (fi) Sovitelma silmänpainemittarissa
ATE555097T1 (de) 4-cycloalkyl-substituierte tetrahydrochinolinderivate und deren verwendung als medikamente
ATE448211T1 (de) 1,2,4-triazinderivate, ihre herstellung und ihre verwendung in der humantherapie